[go: up one dir, main page]

CL2018000457A1 - Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina - Google Patents

Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina

Info

Publication number
CL2018000457A1
CL2018000457A1 CL2018000457A CL2018000457A CL2018000457A1 CL 2018000457 A1 CL2018000457 A1 CL 2018000457A1 CL 2018000457 A CL2018000457 A CL 2018000457A CL 2018000457 A CL2018000457 A CL 2018000457A CL 2018000457 A1 CL2018000457 A1 CL 2018000457A1
Authority
CL
Chile
Prior art keywords
mesothelin
cells
fully human
immune effect
human anti
Prior art date
Application number
CL2018000457A
Other languages
English (en)
Inventor
Huamao Wang
Bo Song
Peng Wang
Original Assignee
Carsgen Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carsgen Therapeutics Ltd filed Critical Carsgen Therapeutics Ltd
Publication of CL2018000457A1 publication Critical patent/CL2018000457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICUERPOS ANTI-MESOTELINA COMPLETAMENTE HUMANOS Y CÉLULAS CON EFECTO INMUNE DIRIGIDO A LA MESOTELINA.
CL2018000457A 2015-08-21 2018-02-20 Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina CL2018000457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510519214 2015-08-21

Publications (1)

Publication Number Publication Date
CL2018000457A1 true CL2018000457A1 (es) 2018-08-24

Family

ID=58099641

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000457A CL2018000457A1 (es) 2015-08-21 2018-02-20 Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina

Country Status (15)

Country Link
US (1) US10793641B2 (es)
EP (1) EP3339326A4 (es)
JP (1) JP6994456B2 (es)
KR (1) KR20180055824A (es)
CN (1) CN106467573B (es)
AU (1) AU2016312015A1 (es)
BR (1) BR112018003339A8 (es)
CA (1) CA2996060A1 (es)
CL (1) CL2018000457A1 (es)
HK (1) HK1251948A1 (es)
IL (1) IL257563A (es)
NZ (1) NZ740855A (es)
RU (1) RU2748281C2 (es)
SG (1) SG11201801351RA (es)
WO (1) WO2017032293A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
SG11202001813UA (en) 2017-08-28 2020-03-30 Shanghai Yile Biotechnology Co Ltd Polypeptide and antibody bound to polypeptide
CN107557336B (zh) * 2017-09-15 2020-02-14 山东兴瑞生物科技有限公司 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
CN107488636A (zh) * 2017-09-30 2017-12-19 山东兴瑞生物科技有限公司 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
JP6339283B1 (ja) 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
CN109971714B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 自表达pd-1抗体并靶向间皮素的嵌合抗原受体修饰t细胞及其用途
CN109608549B (zh) * 2017-12-29 2022-02-18 郑州大学第一附属医院 基于人源间皮素抗体的嵌合抗原受体、慢病毒表达载体及其应用
EP3747433A4 (en) 2018-02-02 2021-12-22 Cafa Therapeutics Limited CELLULAR IMMUNOTHERAPY ASSOCIATION
EP3762410A4 (en) 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania CHEMICAL PROSTATE MEMBRANE SPECIFIC ANTIGEN SPECIFIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
CN119770648A (zh) 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
US12291557B2 (en) * 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
WO2019191340A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019210863A1 (zh) 2018-05-03 2019-11-07 科济生物医药（上海）有限公司 免疫效应细胞及其应用
KR20210018838A (ko) 2018-05-15 2021-02-18 카르스젠 테라퓨틱스 컴퍼니, 리미티드 유전자 조작된 세포 및 응용
CN112368015B (zh) * 2018-06-18 2025-04-29 安维达生物科技公司 细胞因子融合蛋白及其用途
CA3107515A1 (en) 2018-07-24 2020-01-30 Carsgen Therapeutics Co., Ltd. Method for tumor treatment with immune effector cells
CN109097396B (zh) * 2018-09-10 2022-10-11 上海细胞治疗集团有限公司 一种制备靶向间皮素的car-t细胞的方法
EP3892333A4 (en) 2018-12-07 2022-11-30 CRAGE medical Co., Limited Tumor combined immunotherapy
CN111381020B (zh) * 2018-12-27 2024-06-28 上海细胞治疗集团股份有限公司 一种间皮素car-t细胞免疫组化染色试剂盒及其应用
CN109666074B (zh) * 2018-12-29 2020-04-24 广州百暨基因科技有限公司 一种趋化因子受体cxcr5的用途
JP2022524906A (ja) 2019-01-07 2022-05-11 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の組み合わせ
CN109680004B (zh) * 2019-01-09 2025-03-21 上海美丽人生医疗科技有限公司 联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在卵巢癌中的应用
KR102070016B1 (ko) * 2019-01-21 2020-01-29 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
CN113490689B (zh) 2019-02-01 2024-06-04 恺兴生命科技(上海)有限公司 Tcr融合蛋白及表达tcr融合蛋白的细胞
CN110055269B (zh) * 2019-03-20 2021-03-16 英威福赛生物技术有限公司 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途
CA3141085A1 (en) * 2019-06-19 2020-12-24 Brenda Stevens Anti-mesothelin antibodies and immunoconjugates thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231969A1 (en) * 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
CN114364702B (zh) 2020-08-04 2022-09-16 细胞基因股份公司 与间皮素特异性结合的抗-间皮素嵌合抗原受体
WO2022030730A1 (ko) * 2020-08-04 2022-02-10 주식회사 셀렌진 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
WO2022028623A1 (zh) 2020-08-07 2022-02-10 佧珐药业有限公司 工程化改造的细胞以及工程化改造细胞的方法
WO2022078286A1 (zh) * 2020-10-15 2022-04-21 四川科伦博泰生物医药股份有限公司 特异性结合msln的嵌合抗原受体及其应用
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
JP2024527180A (ja) 2021-04-08 2024-07-22 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の使用
AU2022279862B2 (en) * 2021-05-26 2024-02-29 Cellengene Inc Chimeric antigen receptor comprising anti-mesothelin scfv, and use thereof
JP2024523636A (ja) 2021-06-29 2024-06-28 科済生物医薬（上海）有限公司 細胞の生理活性を調節するキメラポリペプチド
KR102860436B1 (ko) * 2021-06-30 2025-09-19 (주)이노베이션바이오 메소텔린 특이적 항체 및 이의 용도
CN115989242A (zh) * 2021-08-16 2023-04-18 上海优替济生生物医药有限公司 间皮素靶向抗体、嵌合抗原受体及其应用
CN113788896A (zh) * 2021-08-25 2021-12-14 南京蓝盾生物科技有限公司 抗msln单克隆内化抗体及其制备方法和应用
CN114015720A (zh) * 2021-09-29 2022-02-08 昆明市延安医院 具有靶向高强度杀瘤活性的Mesothelin嵌合抗原受体修饰的T细胞的制备方法
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023081806A2 (en) * 2021-11-04 2023-05-11 The General Hospital Corporation Anti-mesothelin antibody reagents
TW202332771A (zh) * 2021-12-21 2023-08-16 大陸商深圳市菲鵬生物治療股份有限公司 轉基因免疫細胞及其構建方法和應用
CN114276454B (zh) * 2021-12-29 2022-12-20 华道(上海)生物医药有限公司 一种抗间皮素的纳米抗体及其应用
WO2023138666A1 (en) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
TWI878967B (zh) * 2022-07-11 2025-04-01 中國商諾納生物（蘇州）有限公司 抗間皮素抗體
CN120303294A (zh) * 2022-11-02 2025-07-11 细胞基因股份公司 对间皮素具有增加的亲和力的嵌合抗原受体及其用途
KR20240081499A (ko) * 2022-11-11 2024-06-10 주식회사 유씨아이테라퓨틱스 유전자 조작된 세포 및 이의 용도
CN116003638B (zh) * 2023-01-20 2023-09-05 北京基因启明生物科技有限公司 一种有效杀伤胆管型肝癌的CAR-iNKT细胞技术
WO2025063790A1 (ko) * 2023-09-20 2025-03-27 주식회사 유씨아이테라퓨틱스 항-메소텔린 항체 및 이의 용도
CN117327184B (zh) * 2023-12-01 2024-03-05 赛奥斯博生物科技(北京)有限公司 一种靶向msln的嵌合抗原受体及其应用
CN117843793B (zh) * 2024-03-07 2024-07-09 深圳真实生物医药科技有限公司 抗间皮素抗体、抗原结合片段及其用途
WO2025195483A1 (en) * 2024-03-21 2025-09-25 Utc Therapeutics (Shanghai) Co., Ltd. Mesothelin targetting antibodies, chimeric antigen receptors, and uses thereof
CN119751681A (zh) * 2024-12-30 2025-04-04 北京百替生物技术有限公司 抗间皮素的单链抗体、mRNA及其应用和核酸药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
ES2386367T3 (es) * 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
CN101951946B (zh) * 2007-10-01 2014-12-10 百时美施贵宝公司 结合间皮素的人抗体及其应用
MY157164A (en) * 2007-11-26 2016-05-13 Bayer Ip Gmbh Anti-mesothelin antibodies and uses thereof
CA2718321A1 (en) * 2008-03-27 2009-10-01 Dimiter S. Dimitrov Human anti-mesothelin monoclonal antibodies
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ610976A (en) * 2010-12-20 2015-07-31 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
EP3327037B1 (en) 2012-08-21 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
US10640569B2 (en) * 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
EP3339326A1 (en) 2018-06-27
CN106467573A (zh) 2017-03-01
AU2016312015A1 (en) 2018-04-12
JP6994456B2 (ja) 2022-02-04
RU2748281C2 (ru) 2021-05-21
BR112018003339A2 (pt) 2018-11-21
CA2996060A1 (en) 2017-03-02
US20180244796A1 (en) 2018-08-30
RU2018107802A (ru) 2019-09-23
NZ740855A (en) 2022-04-29
US10793641B2 (en) 2020-10-06
HK1251948A1 (en) 2019-05-03
JP2018529327A (ja) 2018-10-11
BR112018003339A8 (pt) 2022-10-18
KR20180055824A (ko) 2018-05-25
CN106467573B (zh) 2021-05-25
EP3339326A4 (en) 2019-01-09
WO2017032293A1 (zh) 2017-03-02
SG11201801351RA (en) 2018-03-28
RU2018107802A3 (es) 2019-09-23
IL257563A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
IL271110A (en) Antibodies specific for flt3 and their uses
EP3707248A4 (en) MODIFIED IMMUNE CELLS AND THEIR USES
LT3500593T (lt) T ląstelių receptoriai ir imuninė terapija juos naudojant
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
EP3612210A4 (en) MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
HUE047806T2 (hu) Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
GEAP202114450A (en) Anti-tigit antibodies
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
TWD174683S (zh) 戒指
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
DK3166638T3 (da) Nyttelagt-polymer-proteinkonjugater
EP3430036A4 (en) MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY
GT201400061S (es) Diseño de motocicleta
IL259202A (en) Modified immune cells and uses thereof
GT201600009S (es) Motocicleta
GT201500018S (es) Diseño de motocicleta
NI201500046S (es) Motocicleta
GEAP201914386A (en) Francis turbine with short blade and short band
EP3862937C0 (en) GENERATION OF WEATHER FORECASTS USING HOTL SUPERVISION